This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of Sanofi/Regeneron FDA approved therapy, Kevzara (sarilumab), in Polymyalgia rheumatica (PMR)

Ticker(s): SNY, REGN

Who's the expert?

A rheumatologist with experience in treating Polymyalgia rheumatica

Interview Questions
Q1.

Can you please tell us more about Polymyalgia rheumatica and how it affects patients?

Added By: catalin_admin
Q2.

What are the current treatment options for Polymyalgia rheumatica and how effective are they?

Added By: catalin_admin
Q3.

How does Kevzara differ from existing treatments for Polymyalgia rheumatica?

Added By: catalin_admin
Q4.

What is the mechanism of action for Kevzara and how does it work to treat Polymyalgia rheumatica?

Added By: catalin_admin
Q5.

Could you talk about the results of the clinical trials for Kevzara in treating Polymyalgia rheumatica, and how they supported approval?

Added By: catalin_admin
Q6.

How often do patients need to receive Kevzara injections and for how long?

Added By: catalin_admin
Q7.

How much does Kevzara cost, factoring insurance coverage?

Added By: catalin_admin
Q8.

How does Kevzara compare to other drugs in its class for treating autoimmune disorders?

Added By: catalin_admin
Q9.

Are there any long-term risks associated with Kevzara treatment?

Added By: catalin_admin
Q10.

How does Kevzara fit into the overall treatment landscape for autoimmune disorders?

Added By: catalin_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.